AptarGroup has announced its acquisition of Nanopharm and Gateway Analytical as "part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments." The two companies were acquired by Aptar for a total of approximately $50 million. Both will continue to … [Read more...] about Aptar acquires Nanopharm and Gateway Analytical
News
Theravance Biopharma appoints Andrew Hindman as Senior VP and CFO
Theravance Biopharma has named former Acorda Therapeutics Chief Business Officer Andrew Hindman as Senior VP and Chief Financial Officer. Hindman, who led Acorda's acquisition of Inbrija inhaled L-dopa developer Civitas Therapeutics in 2014, also previously served as President and CEO of Tobira Therapeutics and held executive positions at Onyx Pharmaceuticals and … [Read more...] about Theravance Biopharma appoints Andrew Hindman as Senior VP and CFO
Mundipharma gets Australian rights to Penthrox
Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand Managing Director Jane Orr, commented, “Options for pain relief are limited in many clinical … [Read more...] about Mundipharma gets Australian rights to Penthrox
Study demonstrates feasibility of inhaled lipid cisplatin delivery via Windtree’s ADS
Windtree Therapeutics and Eleison Pharmaceuticals have announced results from a study that demonstrated the feasibility of delivering Eleison's inhaled lipid cisplatin (ILC) via Windtree's Aerosol Delivery System (ADS). In March 2018, the companies announced that they had partnered for development of ILC for the treatment of lung cancer. According to the … [Read more...] about Study demonstrates feasibility of inhaled lipid cisplatin delivery via Windtree’s ADS
Verona Pharma initiates Phase 2 trial of RPL554 ensifentrine MDI
Verona Pharma has initiated a Phase 2 trial of the MDI formulation of RPL554 ensifentrine in COPD patients, the company said. Verona recently announced the initiation of a Phase 2b study of nebulized ensifentrine and interim results from a Phase 2 study of the DPI formulation for COPD. The Phase 2 study of the MDI formulation is expected to enroll 36 patients with … [Read more...] about Verona Pharma initiates Phase 2 trial of RPL554 ensifentrine MDI
Study shows ARS-1 intranasal epinephrine has similar PK profile to intramuscular epinephrine
ARS Pharmaceuticals has announced results from the EPI-04 clinical study demonstrating that the company's ARS-1 intranasal epinephrine spray has a pharmacokinetic profile that is similar to intramuscular epinephrine. ARS is developing ARS-1 for the treatment of anaphylaxis, and ARS-1 received Fast Track Designation for that indication earlier this year. The EPI-04 … [Read more...] about Study shows ARS-1 intranasal epinephrine has similar PK profile to intramuscular epinephrine
Afrezza inhaled insulin approved in Brazil
The Brazilian Health Regulatory Agency (ANVISA) has approved Afrezza inhaled insulin for the treatment of diabetes, and the DPI is expected to be launched in Brazil by the end of 2019, MannKind Corporation said. MannKind announced in May 2017 that it had signed a Brazilian distribution deal for Afrezza with Biomm. Afrezza was approved by the FDA in 2014 and is … [Read more...] about Afrezza inhaled insulin approved in Brazil
Clement Clarke launches Clip-Tone inhaler feedback device
Clement Clarke has announced the launch of its Clip-Tone technique guidance whistle for use with GSK's Evohaler Ventolin and Seretide MDIs in the UK. The Clip-Tone will be available by prescription only. Like the company's Flo-Tone inhaler training device, the Clip-Tone provides audio feedback when the patient inhales at the correct inhalation rate, with the tone … [Read more...] about Clement Clarke launches Clip-Tone inhaler feedback device
Phase 3 trial of QVM149 meets primary and secondary endpoints
Novartis has announced that the Phase 3 QUARTZ study met its primary and secondary endpoints, demonstrating that low dose QMF149 indacaterol/mometasone furoate delivered via the Breezhaler DPI produced statistically significant and clinically meaningful lung function and asthma control improvements compared to mometasone furoate alone in adult and adolescent patients … [Read more...] about Phase 3 trial of QVM149 meets primary and secondary endpoints
Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury
Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase device is an electronic atomizer based on a controlled particle dispersion technology platform making use of vortical flow that … [Read more...] about Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury